Bamlanivimab
Based on 1 Customer Validation
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 2423943-37-5
- Molecular Weight:144.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1(K214R) kappa
Virus
SARS-CoV-2
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
YP_009724390.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized SARS-CoV-2 S Protein RBD (HEK293, HY-P73396) can bind Bamlanivimab. The EC50 for this effect is 1.353 ng/mL.
Chemical Information
-
CAS No. 2423943-37-5
-
Appearance Liquid
-
Molecular Weight 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Bamlanivimab]
-
Synonyms
Anti-Human SARS-CoV-2
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)